We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New Products from Aureus Pharma: AurSCOPE®

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Aureus Pharma, a leading provider of knowledge management solutions that accelerate life sciences discovery, announced today the release of three new AurSCOPE® Target knowledge databases. The new offerings include knowledge databases for the important drug targets Nuclear Receptor and Protease, as well as the centralized product AurSCOPE® Global Pharmacology Space (AurSCOPE® GPS). AurSCOPE GPS comprises all of the pharmaceutically important therapeutic targets including G-Protein coupled receptors (GPCR), kinases, ion channels, nuclear receptors and proteases.

Nuclear receptor proteins are integral to critical metabolic processes and implicated in diseases including diabetes, cancer, and heart disease. Likewise, proteases are a major focus for therapeutic intervention being linked to viral diseases including HIV, inflammation and neurogenerative disorders.

AurSCOPE GPS and other AurSCOPE Knowledge databases streamline discovery efforts with thorough assessment of selectivity and off-target effects at the earliest stages of the drug discovery pipeline.

“The release of AurSCOPE Global Pharmacology Space (GPS), Nuclear Receptor and Protease represents an exciting milestone for Aureus Pharma. These powerful new products considerably extend Aureus’ knowledge management solution by providing our pharmaceutical customers unique access to the druggable therapeutic target space.” said Jason Theodosiou, President and CEO of Aureus Pharma. “Using AurSCOPE Knowledge databases, researchers can easily employ knowledge-driven hypotheses to drive better informed decisions during drug discovery.”